more

Recro Pharma, Inc. (REPH)

(Delayed Data from NSDQ)

$9.00 USD

0.00 (0.00%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.99 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?

by Zacks Equity Research Published on December 08,2021

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

REPHNo Net Change

medical

Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research Published on October 01,2021

Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.

REPHNo Net Change

pharmaceuticals

Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research Published on September 16,2021

Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

REPHNo Net Change

Ironwood (IRWD) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research Published on July 29,2021

Ironwood (IRWD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

All You Need to Know About Recro Pharma (REPH) Rating Upgrade to Buy

by Zacks Equity Research Published on July 08,2021

Recro Pharma (REPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

REPHNo Net Change

Is the Options Market Predicting a Spike in Recro Pharma (REPH) Stock?

by Zacks Equity Research Published on December 15,2020

Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.

REPHNo Net Change

Recro Pharma (REPH) in Focus: Stock Moves 7.6% Higher

by Zacks Equity Research Published on June 10,2020

Recro Pharma (REPH) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

medical

Recro Pharma (REPH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on November 08,2019

Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

REPHNo Net Change

Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research Published on October 30,2019

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REPHNo Net Change

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

by Kinjel Shah Published on September 18,2019

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

pharmaceuticals

Will Recro Pharma Continue to Surge Higher?

by Zacks Equity Research Published on August 14,2019

As of late, it has definitely been a great time to be an investor Recro Pharma.

REPHNo Net Change

medical

Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 08,2019

Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

REPHNo Net Change

Recro Pharma (REPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

by Zacks Equity Research Published on July 30,2019

Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

REPHNo Net Change

Catalyst Pharma (CPRX) Rides on Successful Launch of Firdapse

by Zacks Equity Research Published on May 22,2019

Catalyst Pharma (CPRX) gains on the successful launch of Firdapse. The company is looking to develop drug for additional indications.

pharmaceuticals

Catalent Acquires Gene Therapy Leader Paragon Bioservices

by Zacks Equity Research Published on May 21,2019

Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.

pharmaceuticals

New Strong Buy Stocks for May 20th

by Tirthankar Chakraborty Published on May 20,2019

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

by Zacks Equity Research Published on May 14,2019

Catalyst (CPRX) posts narrower-than-expected loss and beats on revenues in the first quarter of 2019.

pharmaceuticals

Recro Pharma (REPH) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on May 10,2019

Recro Pharma (REPH) delivered earnings and revenue surprises of 87.34% and 22.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

REPHNo Net Change

Jazz Pharma (JAZZ) Q1 Earnings and Sales Beat Estimates

by Zacks Equity Research Published on May 08,2019

Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.

pharmaceuticals

Small Drug Stocks Outlook: Near-Term Prospects Encouraging

by Kinjel Shah Published on May 06,2019

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.

pharmaceuticals

Recro Pharma (REPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research Published on May 01,2019

Recro Pharma (REPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.